Select Publications

Bertero C, Chamberlain WM. Breast cancer diagnosis and its treatment affecting the self: A meta-synthesis. Cancer Nurs 2007;30(3):194-202. Abstract

Boehmke MM, Dickerson SS. The diagnosis of breast cancer: Transition from health to illness. Oncol Nurs Forum 2006;33(6):1121-7. Abstract

Bria E et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treat Rev 2006;32(5):325-32. Abstract

Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clin Cancer Res 2006;12(3 Pt 2):1037s-48s. Abstract

Byar KL et al. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum 2006;33(1):E18-26. Abstract

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 6052.

Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum 2006;33(2):265-72. Abstract

Consalvo KE et al. Treating one of our own. Clin J Oncol Nurs 2007;11(2):227-31. Abstract

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract

Forbes JF. The use of early adjuvant aromatase inhibitor therapy: Contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33(2 Suppl 7):2-7. Abstract

Gelmon K et al. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11(Suppl 1):42-51. Abstract

Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract

Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;6(Suppl 2):36-40. Abstract

Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract

Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.

Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41. Abstract

Joensuu H et al. Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Clin Oncol 2006;24(34):5381-7. Abstract

Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract

Heidrich SM et al. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: A comparative study. Oncol Nurs Forum 2006;33(2):315-22. Abstract            

Keller JS. Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 2006;10(1):57-60. Abstract

Limburg CE. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer. Oncol Nurs Forum 2007;34(1):55-63. Abstract

Mandelblat J et al. Capecitabine-docetaxel combination treatment. Expert Rev Anticancer Ther 2006;6(9):1169-78. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Oncology Cooperative Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sledge GW et al. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006;4(21 Suppl 10):1-12. Abstract

Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11(3):361-76. Abstract

Winters L et al. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs 2007;11(3):433-9. Abstract

Table of Contents

Top of Page